Patents Assigned to Zenogen Pharma Co., Ltd.
  • Patent number: 11559543
    Abstract: Provided is an immunostimulator containing: chitosan and/or a chitosan derivative each having a weight-average molecular weight of 10k to 1000k; and an anionic surfactant, the immunostimulator being in particulate form. Also provided are a pharmaceutical composition and an alimentary product, each containing the immunostimulator as an active ingredient.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: January 24, 2023
    Assignee: ZENOGEN PHARMA CO., LTD.
    Inventors: Etsuya Okamoto, Hiroaki Kodama
  • Publication number: 20220145267
    Abstract: In one embodiment, the present invention provides a method for a plurality of cells comprising screening of a part of the cells without subculturing all of the cells and selecting a part of the cells based on the results. In one embodiment, the present invention relates to a method of producing a culture cell, comprising the steps of: a) culturing a plurality of animal cells or plant cells in a culture vessel by adherent culture or on a semisolid medium to form a plurality of colonies each of which is derived from a single cell; b) detecting a sequence of one or more base(s) in a nucleic acid for a part of said plurality of colonies by a nucleic acid or protein detection method, during which said plurality of colonies are cultured in a culture vessel; and c) selecting and collecting said part of the colonies based on the results of said detection method.
    Type: Application
    Filed: March 6, 2020
    Publication date: May 12, 2022
    Inventors: Yuji YOKOUCHI, Takumi ERA, Shinichi SUZUKI
  • Patent number: 11306152
    Abstract: The present invention provides a cancer cell-specific anti-podoplanin antibody or an antigen-binding fragment thereof having an epitope in a Thr85-containing region of an amino acid sequence of human podoplanin represented by SEQ ID NO: 1, the Thr85 having a sialylated O-glycan added thereto.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 19, 2022
    Assignees: Tohoku University, Zenogen Pharma Co., Ltd.
    Inventors: Yukinari Kato, Mika Kato, Shinji Yamada, Satoshi Ogasawara, Takuro Nakamura